NXP-900 is under clinical development by Nuvectis Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NXP-900’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NXP-900 overview

NXP-900 is under development for the treatment of medulloblastoma, triple-negative breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, skin cancer, metastatic castration prostate cancer, pancreatic cancer, colon cancer, esophageal squamous cell carcinoma (ESCC), ovarian clear cell carcinoma, solid tumor and cholangiocarcinoma. It is administered by oral route. The drug candidate acts by targeting Src/Yes1 tyrosine kinase.

Nuvectis Pharma overview

Nuvectis Pharma is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma is headquartered in Fort Lee, New Jersey, the US.

For a complete picture of NXP-900’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.